Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pharm Res. 2010 Jun;27(6):989-98. doi: 10.1007/s11095-010-0051-8. Epub 2010 Jan 27.

Modulating polo-like kinase 1 as a means for cancer chemoprevention.

Author information

  • 1Department of Dermatology, University of Wisconsin, 1300 University Avenue, Medical Science Center, Room 423, Madison, Wisconsin 53706, USA.

Abstract

Naturally occurring agents have always been appreciated for their medicinal value for both their chemopreventive and therapeutic effects against cancer. In fact, the majority of the drugs we use today, including the anti-cancer agents, were originally derived from natural compounds, either in their native form or modified to enhance their bioavailability or specificity. It is believed that for maximum effectiveness, it will useful to design novel target-based agents for chemoprevention as well as the treatment of cancer. Recent studies have shown that the serine/threonine kinase polo-like kinase (Plk) 1 is widely overexpressed in a variety of cancers and is being increasingly appreciated as a target for cancer management. Additionally, several chemopreventive agents have been shown to inhibit Plk1 in cancer cells. In this review, we will discuss if Plk1 could also be a target for designing novel strategies for cancer chemoprevention.

PMID:
20107874
[PubMed - indexed for MEDLINE]
PMCID:
PMC2873067
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk